Lucid Diagnostics Stock Today
| LUCD Stock | USD 1.00 0.04 4.17% |
Performance9 of 100
| Odds Of DistressOver 70
|
Lucid Diagnostics is trading at 1.0 as of the 22nd of November 2024, a 4.17 percent increase since the beginning of the trading day. The stock's lowest day price was 0.98. Lucid Diagnostics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Lucid Diagnostics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 14th of October 2021 | Category Healthcare | Classification Health Care |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange.. The company has 55.45 M outstanding shares of which 422.42 K shares are now shorted by private and institutional investors with about 1.52 trading days to cover. More on Lucid Diagnostics
Moving together with Lucid Stock
Moving against Lucid Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Lucid Stock Highlights
| President COO | Shaun MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsLucid Diagnostics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lucid Diagnostics' financial leverage. It provides some insight into what part of Lucid Diagnostics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lucid Diagnostics (LUCD) is traded on NASDAQ Exchange in USA. It is located in 360 Madison Avenue, New York, NY, United States, 10017 and employs 70 people. Lucid Diagnostics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 55.39 M. Lucid Diagnostics conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 55.45 M outstanding shares of which 422.42 K shares are now shorted by private and institutional investors with about 1.52 trading days to cover.
Lucid Diagnostics currently holds about 34.46 M in cash with (32.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89.
Check Lucid Diagnostics Probability Of Bankruptcy
Ownership AllocationLucid Diagnostics maintains a total of 55.45 Million outstanding shares. Lucid Diagnostics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Lucid Ownership Details
Lucid Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-06-30 | 27 K | |
| Tower Research Capital Llc | 2024-06-30 | 19.8 K | |
| Virtu Financial Llc | 2024-06-30 | 14.2 K | |
| Northern Trust Corp | 2024-09-30 | 13.1 K | |
| First Manhattan Co. Llc | 2024-06-30 | 12.6 K | |
| Resources Investment Advisors Inc | 2024-09-30 | 11.2 K | |
| Byrne Asset Management Llc | 2024-06-30 | 11 K | |
| Jones Financial Companies Lllp | 2024-06-30 | 3.8 K | |
| Wells Fargo & Co | 2024-06-30 | 3.5 K | |
| Luminus Management, Llc | 2024-09-30 | 1.2 M | |
| Vanguard Group Inc | 2024-09-30 | 560.9 K |
Lucid Diagnostics Historical Income Statement
Lucid Stock Against Markets
Lucid Diagnostics Corporate Management
| Michael Gordon | General Secretary | Profile | |
| Lishan MD | Chairman CEO | Profile | |
| Joseph MD | Strategic Cofounder | Profile | |
| Michael Parks | Vice Relations | Profile | |
| Adrian Miller | VP Relations | Profile | |
| Amitabh MD | Strategic Cofounder | Profile | |
| Deepika Lakhani | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.09 | Quarterly Revenue Growth 0.497 | Return On Assets (1.01) | Return On Equity (10.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.